An industry perspective on the role and utility of animal models of pain in drug discovery

Neuroscience Letters

Volumn 557, Issue , 2013, Pages 65-72

  Whiteside, Garth T ^a   Pomonis, James D ^b   Kennedy, Jeffrey D ^c  

^a Purdue Pharma Discovery Research   (United States)

^b Algos Preclinical Services   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Analgesic drug development; Predictive validity; Translational models

Indexed keywords

DULOXETINE; GABAPENTIN;

ALLODYNIA; ANALGESIA; ANIMAL BEHAVIOR; ANIMAL MODEL; CANINE MODEL; DISEASE COURSE; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; EFFECT SIZE; ELECTROENCEPHALOGRAM; FIBROMYALGIA; INFLAMMATORY PAIN; NERVE INJURY; NOCICEPTIVE PAIN; NONHUMAN; OSTEOARTHRITIS; PAIN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; RHEUMATOID ARTHRITIS; RODENT MODEL; SLEEP DISORDER; STRUCTURE ACTIVITY RELATION; TAIL FLICK TEST; THERMAL INJURY;

ANALGESIC DRUG DEVELOPMENT; PREDICTIVE VALIDITY; TRANSLATIONAL MODELS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; PAIN; RATS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84890157151     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.08.033     Document Type: Review

References (45)

1. Andrews N., Legg E., Lisak D., Issop Y., Richardson D., Harper S., Pheby T., Huang W., Burgess G., Machin I., Rice A.S.C. Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain. Eur. J. Pain 2012, 16:485-495.
2. Baron R., Förster M., Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol. 2012, 11:999-1005.
3. Blackburn-Munro G. Pain-like behaviours in animals - how human are they?. Trends Pharmacol. Sci. 2004, 25:299-305.
4. Blackshaw L.A. Visceral pain readouts in experimental medicine. Neurogastroenterol. Motil. 2012, 24:891-894.
5. Brown D.C., Boston R.C., Coyne J.C., Farrar J.T. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J. Am. Vet. Med. Assoc. 2008, 233:1278-1283.
6. Chappell A.S., Desaiah D., Liu-Seifert H., Zhang S., Skljarevski V., Belenkov Y., Brown J.P. Placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2010, 11:33-41.
7. Dworkin R.H., Turk D.C., Wyrwich K.W., Beaton D., Cleeland C.S., Farrar J.T., Haythornthwaite J.A., Jensen M.P., Kerns R.D., Ader D.N., Brandenburg N., Burke L.B., Cella D., Chandler J., Cowan P., Dimitrova R., Dionne R., Hertz S., Jadad A.R., Katz N.P., Kehlet H., Kramer L.D., Manning D.C., McCormick C., McDermott M.P., McQuay H.J., Patel S., Porter L., Quessy S., Rappaport B.A., Rauschkolb C., Revicki D.A., Rothman M., Schmader K.E., Stacey B.R., Stauffer J.W., von Stein T., White R.E., Witter J., Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J. Pain 2008, 9:105-121.
8. Farrar J.T., Young J.P., LaMoreaux L., Werth J.L., Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158.
9. Gavva N.R., Treanor J.J., Garami A., Fang L., Surapaneni S., Akrami A., Alvarez F., Bak A., Darling M., Gore A., Jang G.R., Kessiak J.P., Ni L., Norman M.H., Palluconi G., Rose M.J., Salfi M., Tan E., Romanovsky A.A., Banfield C., Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008, 136:202-210.
10. Granmo M., Jensen T., Schouenborg J. Nociceptive transmission to rat primary somatosensory cortex - comparison of sedative and analgesic effects. PLoS ONE 2013, 8:e53966.
11. Hill R. NK1 (substance P) receptor antagonists - why are they not analgesic in humans?. Trends Pharmacol. Sci. 2000, 21:244-246.
12. Huang W., Calvo M., Karu K., Olausen H.R., Bathgate G., Okuse K., Bennett D.L.H., Rice A.S.C. A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy. Pain 2013, 154:560-575.
13. Huggins J.P., Smart T.S., Langman S., Taylor L., Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012, 153:1837-1846.
14. Hummel M., Lu P., Cummons T.A., Whiteside G.T. The persistence of a long-term negative affective state following the induction of either acute or chronic pain. Pain 2008, 140:436-445.
15. Huntjens D.R., Spalding D.J., Danhof M., Della Pasqua O.E. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. Eur. J. Pain 2009, 13:448-457.
16. Ioannidis J.P.A. Why most published research findings are false. PLoS Med. 2005, 2:e124.
17. Joshi S.K., Honore P. Animal models of pain for drug discovery. Expert Opin. Drug Discov. 2006, 1:341-352.
18. King T., Vera-Portocarrero L., Gutierrez T., Vanderah T.W., Dussor G., Lai J., Fields H.L., Porreca F. Unmasking the tonic-aversive state in neuropathic pain. Nat. Neurosci. 2009, 12:1364-1366.
19. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
20. Langford D.J., Bailey A.L., Chanda M.L., Clarke S.E., Drummond T.E., Echols S., Glick S., Ingrao J., Klassen-Ross T., LaCroix-Fralish M.L., Matsumiya L., Sorge R.E., Sotocinal S.G., Tabaka J.M., Wong D., van den Maagdenberg A.M.J.M., Ferrari M.D., Craig K.D., Mogil J.S. Coding of facial expressions of pain in the laboratory mouse. Nat. Methods 2010, 7:447-449.
21. Lau W., Dykstra C., Thevarkunnel S., Silenieks L.B., de Lannoy I.A.M., Lee D.K.H., Higgins G.A. A back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain. Neuropharmacology 2013, June. pii: S0028-3908(13)00237-2.
22. Leys L.J., Chu K.L., Xu J., Pai M., Yang H.S., Robb H.M., Jarvis M.F., Radek R.J., McGaraughty S. Disturbances in slow-wave sleep are induced by models of bilateral inflammation, neuropathic, and postoperative pain, but not osteoarthritic pain in rats. Pain 2013, 154:1092-1102.
23. Mao J. Current challenges in translational pain research. Trends Pharmacol. Sci. 2012, 33:568-573.
24. Marker C.L., Pomonis J.D., Gottshall S.L. Abstract, measuring use-related pain in a rat model of osteoarthritis. 13th IASP World Congress on Pain 2010.
25. Mogil J.S. Animal models of pain: progress and challenges. Nat. Rev. Neurosci. 2009, 10:283-294.
26. Negus S.S., Vanderah T.W., Brandt M.R., Bilsky E.J., Becerra L., Borsook D. Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J. Pharmacol. Exp. Ther. 2006, 319:507-514.
27. Oertel B.G., Lötsch J. Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research. Br. J. Pharmacol. 2013, 168:534-553.
28. Pande A.C., Pyke R.E., Greiner M., Cooper S.A., Benjamin R., Pierce M.W. Analgesic efficacy of the kappa-receptor agonist, enadoline, in dental surgery pain. Clin. Neuropharmacol. 1996, 19:92-97.
29. Pereira Do Carmo G., Stevenson G.W., Carlezon W.A., Negus S.S. Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain 2009, 144:170-177.
30. Piesla M.J., Leventhal L., Strassle B.W., Harrison J.E., Cummons T.A., Lu P., Whiteside G.T. Abnormal gait, due to inflammation but not nerve injury, reflects enhanced nociception in preclinical pain models. Brain Res. 2009, 1295:89-98.
31. Prinz F., Schlange T., Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets?. Nat. Rev. Drug Discov. 2011, 10:328-329.
32. Quiding H., Jonzon B., Svensson O., Webster L., Reimfelt A., Karin A., Karlsten R., Segerdahl M. TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction. Pain 2013, 154:808-812.
33. Rice A.S.C., Cimino-Brown D., Eisenach J.C., Kontinen V.K., Lacroix-Fralish M.L., Ian Machin (on behalf of the Preclinical Pain Consortium), Mogil J.S., Stohr T. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 2008, 139:243-247.
34. Rice A.S.C., Morland R., Huang W., Currie G.L., Sena E.S., Macleod M.R. Transparency in the reporting of in vivo pre-clinical pain research: the relevance and implications of the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines. Scand. J. Pain 2013, 4:58-62.
35. Rowbotham M., Harden N., Stacey B., Bernstein P., Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. J. Am. Med. Assoc. 1998, 280:1837-1842.
36. Sena E.S., van der Worp H.B., Bath P.M.W., Howells D.W., Macleod M.R. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010, 8:e1000344.
37. Silva A., Andersen M.L., Tufik S. Sleep pattern in an experimental model of osteoarthritis. Pain 2008, 140:446-455.
38. Stevenson G.W., Cormier J., Mercer H., Adams C., Dunbar C., Negus S.S., Bilsky E.J. Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. Life Sci. 2009, 85:309-315.
39. Sufka K. Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain. Pain 1994, 58:355-366.
40. Taneja A., Di lorio V.L., Danhof M., Della Pasqua O. Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. Drug Discov. Today 2012, 17:837-849.
41. van der Kam E.L., Vry J.D., Schiene K., Tzschentke T.M. Differential effects of morphine on the affective and the sensory component of carrageenan-induced nociception in the rat. Pain 2008, 136:373-379.
42. van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O'Collins V., Macleod M.R. Can animal models of disease reliably inform human studies?. PLoS Med. 2010, 7:e1000245.
43. Vierck C.J., Hansson P.T., Yezierski R.P. Clinical and pre-clinical pain assessment: are we measuring the same thing?. Pain 2008, 135:7-10.
44. Walton M.B., Cowderoy E., Lascelles D., Innes J.F. Evaluation of construct and criterion validity for the 'Liverpool Osteoarthritis in Dogs' (LOAD) clinical metrology instrument and comparison to two other instruments. PLoS ONE 2013, 8:e58125.
45. Whiteside G.T., Adedoyin A., Leventhal L. Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans. Neuropharmacology 2008, 54:767-775.